Cite
Axicabtagene-ciloleucel/dexamethasone/tocilizumab: Cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and lack of efficacy: case report.
MLA
“Axicabtagene-Ciloleucel/Dexamethasone/Tocilizumab: Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome and Lack of Efficacy: Case Report.” Reactions Weekly, vol. 1940, no. 1, Jan. 2023, p. 91. EBSCOhost, https://doi.org/10.1007/s40278-023-31949-1.
APA
Axicabtagene-ciloleucel/dexamethasone/tocilizumab: Cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and lack of efficacy: case report. (2023). Reactions Weekly, 1940(1), 91. https://doi.org/10.1007/s40278-023-31949-1
Chicago
“Axicabtagene-Ciloleucel/Dexamethasone/Tocilizumab: Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome and Lack of Efficacy: Case Report.” 2023. Reactions Weekly 1940 (1): 91. doi:10.1007/s40278-023-31949-1.